医学
肝硬化
胃肠病学
内科学
瞬态弹性成像
纤维化
临床终点
安慰剂
肝活检
脂肪变性
代理终结点
脂肪性肝炎
肝病
肝纤维化
脂肪肝
随机对照试验
活检
病理
疾病
替代医学
作者
Rohit Loomba,Mazen Noureddin,Kris V. Kowdley,Anita Kohli,Aasim Sheikh,Guy Neff,Bal Raj Bhandari,Nadege Gunn,Stephen H. Caldwell,Zachary Goodman,Ilan Wapinski,Murray B. Resnick,Andrew H. Beck,Dora Ding,Catherine Jia,Jen‐Chieh Chuang,Ryan S. Huss,Chuhan Chung,G. Mani Subramanian,Robert P. Myers
出处
期刊：Hepatology
[Lippincott Williams & Wilkins]
日期：2020-11-10
卷期号：73 (2): 625-643
被引量：261
摘要
In patients with bridging fibrosis and cirrhosis, 48 weeks of cilofexor/firsocostat was well tolerated, led to improvements in NASH activity, and may have an antifibrotic effect. This combination offers potential for fibrosis regression with longer-term therapy in patients with advanced fibrosis attributable to NASH.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
大力的灵雁
GingerF
向北要上岸
Accept
嘻嘻哈哈
殷勤的紫槐
捈荼
互助
Kamaria
无极微光
dynamoo
嘉心糖
愔愔
ZijingCao
月亮不睡我不睡
tiptip
cookies
Li
ElioHuang
华仔
皖公网安备34019202002308
